Insilico and Hygtia dose ISM8969 in humans for the first time: a brain-penetrant NLRP3 inhibitor for neuroinflammation
Insilico and Hygtia dose ISM8969 in humans for the first time: a pill targeting the NLRP3 inflammasome is being tested as a potential drug for neuroinflammation and brain diseases
ISM8969 has entered Phase I in Australia. The trial will assess safety, dosing, drug levels in blood and cerebrospinal fluid, and the inflammatory marker hsCRP in participants with obesity and cardiovascular risk. Parkinson’s disease remains a future target, not a validated indication.
On June 17, Insilico reported that the first person had received ISM8969 in a Phase I clinical trial. It is a brain-penetrant small-molecule NLRP3 inhibitor that the company is developing with Hygtia Therapeutics for chronic neuroinflammation and central nervous system diseases.
NLRP3 is part of the innate immune system. Put simply, a cell senses danger, assembles an inflammatory complex, and triggers signals such as IL-1 beta and IL-18. When that system stays switched on for too long, it is linked to age-related inflammation, tissue damage, and neurodegeneration.
There is an important nuance here: the current trial is not treating Parkinson’s disease. On ClinicalTrials.gov, the record NCT07581431 describes healthy adults, one cohort of older participants aged 65-80, and adults with obesity, elevated hsCRP, and cardiovascular risk factors. People with a history of central nervous system disease are excluded from the protocol.
Phase I does different work. It tests what doses people can tolerate, how quickly the drug appears in and clears from the blood, and what happens to lab values, ECGs, and adverse events. In the multiple-dose part, participants will take ISM8969 for up to 14 days.
The strongest part of the protocol is cerebrospinal fluid. Researchers will collect samples to see whether ISM8969 actually reaches the place where it needs to work, rather than leaving “brain-penetrant” as a phrase in a press release. For a neuroinflammation drug, that is an early filter: blood is easy to measure, but brain exposure has to be proven separately.
That sets ISM8969 apart from the adjacent BioAge story. BioAge is advancing BGE-102 through a cardiovascular risk path: obesity, hsCRP, 12 weeks, and dose selection for a future larger study. Insilico is taking the brain route instead: a short Phase I study, cerebrospinal fluid, and a future neurodegeneration program. The target is the same, but the path into medicine is different.
ISM8969 did not appear out of nowhere. In January, Insilico received FDA IND clearance for the molecule and signed a deal with Hygtia: the parties each hold 50% of global rights, Insilico is leading the IND and Phase I work, and Hygtia is expected to take over later clinical stages and commercialization. Insilico may receive up to $66 mln in upfront and milestone payments.
The company emphasizes that Chemistry42, its generative chemistry platform, helped optimize the molecule for blood-brain barrier penetration. That barrier separates the blood from brain tissue and blocks many substances. What matters next are lumbar puncture, drug concentration in cerebrospinal fluid, tolerability, and dose selection.
The NLRP3 field is no longer a one-company story. NodThera has NT-0796, another oral NLRP3 inhibitor; in 2025, Movement Disorders published a paper in Parkinson’s disease patients showing that 28 days of therapy reduced markers of neuroinflammation and systemic inflammation. So ISM8969 should not be framed as the first clinical attempt at the entire idea. It is the first-in-human dose for this particular molecule and the first clinical step for the Insilico/Hygtia partnership.
For longevity medicine, this looks like ordinary, almost boring medicine. Age-related inflammation reaches the clinic through specific diseases, short early-stage trials, biomarkers, cerebrospinal fluid, and a protocol in which a big theory turns into something measurable.